Form 4: ARS Pharmaceuticals Chief Medical Officer Sells Shares Under 10b5-1 Plan

Sarina Tanimoto, Chief Medical Officer of ARS Pharmaceuticals, sold 100,000 shares of common stock under a pre-arranged 10b5-1 trading plan.

Summary

• Sarina Tanimoto, the Chief Medical Officer of ARS Pharmaceuticals, sold a total of 100,000 shares of the company's common stock on November 19, 2024.
• The sales were executed under a pre-arranged Rule 10b5-1 trading plan established on March 31, 2023.
• 50,000 shares were sold at a weighted average price of $13.9502, with prices ranging from $13.50 to $14.25.
• Another 50,000 shares were sold at a weighted average price of $13.949, with prices ranging from $13.50 to $14.28.
• Following these transactions, Ms. Tanimoto directly owns 3,407,847 shares and indirectly owns shares through various trusts.
• The report also details indirect ownership through the Sarina Tanimoto Charitable Remainder UniTrust, the Lowenthal-Tanimoto Family Trust, the Richard E. Lowenthal Charitable Remainder UniTrust, and shares owned by her spouse.

Sentiment

Score: 5

Explanation: The document reports a routine insider sale under a pre-arranged plan, which is neither particularly positive nor negative.

Risks

• Sales by insiders can sometimes be perceived negatively by the market, potentially impacting the stock price.

Industry Context

Insider trading activity is a common occurrence in publicly traded companies, and these transactions are closely monitored by regulators and investors.

Comparison to Industry Standards

• Rule 10b5-1 trading plans are a common mechanism for corporate insiders to sell shares while avoiding accusations of trading on non-public information.
• The reported sales are within the typical range of insider transactions for a company of this size and stage.
• It is common for executives to diversify their holdings, and these sales do not necessarily indicate a negative outlook on the company's future.

Stakeholder Impact

• The sales may have a minor impact on shareholder sentiment, but are unlikely to cause significant concern given the pre-planned nature of the transactions.

Key Dates

Keywords

insider trading, Form 4, Rule 10b5-1, stock sale, ARS Pharmaceuticals, Sarina Tanimoto, SPRY, chief medical officer